Results 81 to 90 of about 3,273 (206)

Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss

, 2005
peer reviewedIn postmenopausal osteoporosis, the administration of alfacalcidol to women resulted in an increase in trabecular bone mineral density (BMD), prevention of cortical bone loss, and a significant reduction in the incidence of further vertebral
Lecart, M. P., Reginster, Jean-Yves, Richy, F.   +2 more
core  

ACTIVE VITAMIN D METABOLITES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS

Медицинский совет, 2017
The article presents the basic definitions related to the treatment of postmenopausal osteoporosis, and certain sections from the guidelines of the Russian Association on Osteoporosis (2016) dedicated to the prescription of active vitamin D metabolites ...
O. V. Yakushevskaya
doaj   +1 more source

High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use. Extension of the Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis-trial

, 2010
ObjectiveIn the 18 month "alendronate or alfacalcidol in glucocorticoid-induced osteoporosis"-trial (STOP-trial) patients with rheumatic diseases who started glucocorticoids were randomised to anti-osteoporosis therapy with either daily alendronate (10 ...
Jacobs, J. W. G., Hulsmans, H. M. J., Hoes, J. N., Bijlsma, Johannes W J, de Nijs, R. N. J. T. L., Lems, Willem F., Bruyn, G. A. W., Geusens, P. P. M. M.   +7 more
core  

Vitamin D metabolism in diabetic nephropathy

Ожирение и метаболизм
Diabetic nephropathy (DN) is a specific kidney involvement in diabetes mellitus (DM), caused by hemodynamic and metabolic factors. In the kidneys takes place an important step in the metabolism of vitamin D — 1α-hydroxylation, which results in the ...
Z. V. Abilov, R. Kh. Salimkhanov, A. A. Povaliaeva, A. Yu. Zhukov, E. A. Pigarova, L. K. Dzeranova, L. Ya. Rozhinskaya   +6 more
doaj   +1 more source

No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial

, 2011
Alfacalcidol and paricalcitol are vitamin D analogs used for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease, but have known dose-dependent side effects that cause hypercalcemia and hyperphosphatemia.
Madsen, Jens, Henning Danielsen, Peter Marckmann, Bacevicius, Egidijus, Ditte Hansen, Egidijus Bacevicius, Hansen, Ditte, Nielsen, Eva, Nielsen, Jørgen E., Peter Thye-Roenn, Jørgen E. Nielsen, Birgitte G. Tougaard, Tougaard, Birgitte G., Lauridsen, Thomas G., Thomas G. Lauridsen, Rasmussen, Knud, Thye-Roenn, Peter, Knud Rasmussen, Jens K. Madsen, Svend Kreiner, Marckmann, Peter, Meyer-Hofmann, Helmut, Kreiner, Svend, Brandi, Lisbet, Lauridsen, Thomas Guldager, Tougaard, Birgitte G, Helmut Meyer-Hofmann, Lisbet Brandi, Madsen, Jens Kristian, Madsen, Jens K., Nielsen, Jørgen Erik, Danielsen, Henning   +31 more
core   +1 more source

Osteoprotective effect of propranolol in ovariectomized rats: a comparison with zoledronic acid and alfacalcidol

, 2013
Currently beta-adrenergic receptor blockers are considered to be potential drugs under investigation for preventive or therapeutic effect in osteoporosis.
Bhat, MR, Khajuria, Deepak Kumar, Razdan, Rema, Mahapatra, Roy D   +3 more
core   +1 more source

Immunomodulatory effect of alfacalcidol in patients with active rheumatoid arthritis [PDF]

, 2016
Poslednjih godina, otkriće ekspresije vitamin-D receptora (VDR) u ćelijama imunskog sistema i činjenica da neke od ovih ćelija i produkuju D hormon, govore u prilog postojanja imunomodulatorne uloge vitamina D u organizmu.
Živanović Radnić, Tatjana V.
core   +1 more source

Differences of therapeutic effects on regional bone mineral density and markers of bone mineral metabolism between alendronate and alfacalcidol in Japanese osteoporotic women [PDF]

, 2007
We studied the differences of therapeutic effects on regional bone mineral density (BMD) and markers of bone mineral metabolism between alendronate and alfacalcidol in Japanese osteoporotic women.
Yasui, Natsuo, 00157984, Abbaspour, Aziz, Yonezu, Hiroshi, ヤスイ, ナツオ, 安井, 夏生, 1520, 米津, 浩, タカタ, シンジロウ, Takata, Shinjiro, 60032/profile-ja.html, ヨネヅ, ヒロシ, 髙田, 信二郎   +12 more
core  

[Alendronate more effective than alfacalcidol in the prevention of osteoporosis in patients with rheumatic disease who are starting glucocorticoid therapy]

, 2007
Contains fulltext : 52836.pdf (Publisher’s version ) (Open Access)OBJECTIVE: To compare the effects of alendronate and alfacalcidol in the prevention ofglucocorticoid-related osteoporosis in patients with a rheumatic disease.
Laan, R.F.J.M., Geusens, P.P., Lems, W.F., Buskens, E., Bruyn, G.A.W., Huisman, A.M., Jacobs, J.W., Bijlsmat, J.W., Nijs, R.N. de, Laet, C.E. de, Algra, A., Dijkmans, B.A.C., Oostveen, J.C.   +12 more
core  

Beurteilung des Knochenstoffwechsels bei Patienten mit chronischer Herzinsuffizienz - 1-Alfacalcidol als Prävention und Therapie der sekundären Osteoporose [PDF]

, 2006
Fortschreitender Knochenmasseverlust und sekundäre Osteoporose sind häufige Komplikationen bei Patienten mit chronischer Herzinsuffizienz. Aufgrund von Schmerzen, spontanen Frakturen und eventuell dauerhafter Immobilisation werden die ohnehin schon ...
Ackermann, Dorothee
core